Title: Mtor Inhibitor Rad001 Promotes Metastasis in a Rat Model of Pancreatic Neuroendocrine

نویسندگان

  • Stefan E. Pool
  • S. Bison
  • Stuart J. Koelewijn
  • Linda M. van der Graaf
  • Marleen Melis
  • Eric P. Krenning
  • Marion de Jong
چکیده

1 cancer 2 3 Authors and Affiliations: Stefan E. Pool, S. Bison, Stuart J. Koelewijn, Linda M. van der Graaf, 4 Marleen Melis, Eric P. Krenning, Marion de Jong 5 6 Department of Nuclear Medicine and Radiology, Erasmus MC, Rotterdam, the Netherlands 7 8 None of the authors has a conflict of interest to declare. 9 10 Running title: Augmentation of metastatic tumor behavior by mTOR inhibition. 11 12

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer.

Inhibition of mTOR is commonly considered a valid target in cancer treatment, but this assertion does not address effects on the immune microenvironment that may be detrimental to cancer treatment. Here we show how administration of the mTOR inhibitor RAD001 (everolimus) results in the occurrence of distant metastasis in a rat model of pancreatic cancer. RAD001 was administered twice weekly for...

متن کامل

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.

BACKGROUND/AIM Tumors exhibiting constitutively activated PI(3)K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including neuroendocrine tumors (NETs). However, no preclinical data about the effects of RAD001 on NET cells have been published. In this study, we aimed...

متن کامل

Clinical Neuroendocrinology and Neuroendocrine Tumors

Background/Aim: Tumors exhibiting constitutively activated PI(3)K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including neuroendocrine tumors (NETs). However, no preclinical data about the effects of RAD001 on NET cells have been published. In this study, we aime...

متن کامل

Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus

Pancreatic neuroendocrine tumors (PanNETs) are frequently diagnosed at unresectable stage and remain a medical challenge. Everolimus (RAD001, Afinitor(®), Novartis, Basel, Switzerland), an orally administered inhibitor of mammalian target of rapamycin (mTOR), was recently approved by the Food and Drug Administration to treat patients with advanced PanNETs. This review will examine the mechanism...

متن کامل

Breast metastasis from the pancreatic neuroendocrine tumor origin detected by 99mTc-Octreotate scan

A 50 years old woman with history of pancreatic neuroendocrine tumor diagnosed 2 years ago, which has not been surgically removed,was referred to our department for a 99mTc-Octreotate in order to evaluate the somatostatin receptor status. She was treated with regular sandostatin injections and chemotherapy. Her CT scan which was previously performed confirmed lung, adrenal and hepati...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2012